Adjuvant chemotherapy for non-small-cell lung cancer : a New Zealand perspective

Reviews recent developments with the use of adjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) and the implications of these developments for healthcare. Predicts that adjuvant chemotherapy for NSCLC could prevent up to 15 lung cancer deaths each year for relatively low drug expenditure, particularly among Māori, among whom NSCLC is over-represented. Recommends revision of PHARMAC policy regarding eligibility for adjuvant chemotherapy with cisplatin plus vinorelbine. Source: National Library of New Zealand Te Puna Matauranga o Aotearoa, licensed by the Department of Internal Affairs for re-use under the Creative Commons Attribution 3.0 New Zealand Licence.